Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14868424 | 0.77 | — | — | |
| SCHEMBL14868479 | 0.75 | ALOX5 (0.32) | SMN1; SMN2 | |
| SCHEMBL20799765 | 0.73 | RAB9A (0.38) | ALDH1A1MEN1KMT2A | |
| SCHEMBL14868454 | 0.67 | HTR3E (0.33) | — | |
| SCHEMBL10525574 | 0.66 | LMNA (0.35) | SMN1; SMN2ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL3577961 | 0.66 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL1694938 | 0.66 | LMNA (0.41) | SMN1; SMN2ALDH1A1LMNATMEM97MEN1 | |
| SCHEMBL13713225 | 0.66 | RIPK1 (0.43) | SMN1; SMN2ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL14868507 | 0.65 | ADRA2A (0.33) | — | |
| SCHEMBL9547540 | 0.65 | CES2 (0.39) | SMN1; SMN2ALDH1A1LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMACEUTICALS INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | ANJI PHARMACEUTICALS INC. | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11759441-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | SMN1; SMN2 4216/4885ALDH1A1 980/4885LMNA 2222/4885 |
| US-20220151957-A1 | BIGUANIDE COMPOSITIONS AND METHODS OF TREATING METABOLIC DISORDERS | SLC5A2, SLC5A1, GPR119 | SMN1; SMN2 4216/4885ALDH1A1 980/4885LMNA 2222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.